| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Tulathromycin |
| CAS | 280755-12-6 |
| Appearance | White crystalline powder |
| MF | C41H79N3O12 |
| MW | 806.08 |
| Purity | 99% |
| Shelf Life | 2 Years |
Tulathromycin is mainly used for the respiratory diseases of pigs and cattle caused by actinobacillus, mycoplasma, pasteurella and haemophilus parahaemophilus.
It has many advantages, such as low dosage, single dose, low residue and special for animals.
• Tulathromycin is a macrolide antibiotic used to treat bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs.
• Clinical effectiveness of tulathromycin 217500-96-4, a novel triamilide antimicrobial, for the control of respiratory disease in cattle at high risk for developing bovine respiratory disease.
The efficacy of tulathromycin 217500-96-4 in decreasing the incidence of morbidity and mortality due to bovine respiratory disease (BRD) in 1,239 high-risk cattle was investigated at four US feedlots. Calves not exhibiting clinical signs of BRD received one of three treatments administered subcutaneously in the neck: physiologic saline at 0.02 ml/kg, tulathromycin 217500-96-4 at 2.5 mg/kg, or tilmicosin at 10 mg/kg. Each treatment group consisted of 413 calves. Calves with clinical signs of BRD and rectal temperatures of 104 degrees F or higher on days 1 through 14 were considered treatment failures (BRD morbidity). Nasopharyngeal swabs from saline-treated morbidities were submitted for isolation and identification of BRD organisms. Respiratory disease morbidity was highest in calves treated with saline and significantly (P < or = .0001) lower in calves administered tulathromycin 217500-96-4 or tilmicosin. Morbidity from BRD was significantly (P < or = .0001) higher in calves treated with tilmicosin than in calves treated with tulathromycin 217500-96-4. Under conditions of this study, tulathromycin 217500-96-4, given to calves at high risk of developing BRD, was significantly more effective in reducing BRD morbidity when compared to both saline- and tilmicosin-treated calves.
){kind=link}